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Our objectivewas to characterize the distribution, diversity and patterns of hepatitis C
virus (HCV) genotypes in theMiddle East andNorthAfrica (MENA). Source of datawas
a database of HCV genotype studies in MENA populated using a series of systematic
literature searches. Pooledmeanproportionswereestimated for each genotype andby
country using DerSimonian-Laird random-effects meta-analyses. Genotype diversity
within countries was assessed using Shannon Diversity Index. Number of chronic
infections by genotype and country was calculated using the pooled proportions and
country-specific numbers of chronic infection. Analyses were conducted on 338
genotype studies including 82 257 genotyped individuals. Genotype 1 was dominant
(≥50%) in Algeria, Iran, Morocco, Oman, Tunisia, and UAE, and was overall ubiquitous
across the region. Genotype 2 was common (10-50%) in Algeria, Bahrain, Libya, and
Morocco. Genotype 3 was dominant in Afghanistan and Pakistan. Genotype 4 was
dominant in Egypt, Iraq, Jordan, Palestine, Qatar, Saudi Arabia, and Syria. Genotypes 5,
6, and 7 had limited or no presence across countries. Genotype diversity varied
immensely throughout MENA. Weighted by population size, MENA's chronic
infections were highest among genotype 3, followed by genotype 4, genotype 1,
genotype 2, genotype 5, and genotype 6. Despite ubiquitous presence of genotype 1,
the vast majority of chronic infections were of genotypes 3 or 4, because of the sizable
epidemics in Pakistan and Egypt. Three sub-regional patterns were identified:
genotype 3 pattern centered in Pakistan, genotype 4 pattern centered in Egypt, and
genotype 1 pattern ubiquitous in most MENA countries.
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1 | INTRODUCTION
Hepatitis C virus (HCV) is a blood-borne pathogen, with themajority of
chronically infected individuals showing clinical manifestations 20-30
years after the onset of infection.1 Chronic HCV infection causes
severalmorbidities, such as liver cirrhosis and liver cancer, and is amain
indication for liver transplantation.2–4 HCV related morbidity and
mortality place a burden on healthcare systems worldwide, as an
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estimated 62-79 million people are chronically infected, globally.5 The
Middle East and North Africa (MENA) region is the most affected by
HCV infection, with over 15 million chronically infected individuals.5,6
HCV demonstrates substantial genetic diversity and can be classified
intosevenmaingenotypes,numberedfromonetoseven, and67subtypes.7
HCV genotype distribution varies across the globe.7,8 Genotypes 1 and
threeareprevalentgenotypesworldwide,whilegenotypetwo iscommon in
West Africa and South America, and genotypes 4 and 6 are common in
Central/North Africa and East/Southern Asia, respectively.7,8
Knowledge of HCV genotype distribution, diversity, and patterns
contribute to effective control ofHCV infection.9Genotype distribution
can reveal inferences about the modes of transmission and sources of
infection.7,10 Importantly, HCV genotype is a predictor of response to
direct-acting antiviral (DAA) treatment, and is therefore integral in
selection and duration of interferon-free DAA regimens.11 As such, this
study aims to characterize the distribution, diversity, and patterns of
HCV genotypes in MENA by (1) estimating the country-specific pooled
mean proportions of HCV genotypes; (2) assessing the country-specific
genotype diversity; and (3) estimating the country-specific number of
chronically infected individuals by genotype. This study was conducted
under the umbrella of the MENA HCV Epidemiology Synthesis Project,
an on-going effort to characterize HCV epidemiology and inform key
public health research, policy and programming priorities inMENA.12–20
2 | MATERIALS AND METHODS
2.1 | Data sources
The source of data for our study was the MENA HCV Epidemiology
Synthesis Project database, a comprehensive database of HCV
epidemiological measures.12–20 The database consists of several
sub-databases such as an HCV genotype frequency sub-database
comprised of 338 HCV genotype studies among 82 257 participants,
an HCV antibody prevalence sub-database comprised of 2543
antibody prevalence studies among 51 598 736 participants, and an
HCV RNA prevalence (among antibody positive persons) database
comprised of 178 RNA prevalence studies among 19 593 HCV
antibody positive participants. The MENA HCV Epidemiology
Synthesis Project database was populated through a series of
systematic reviews for HCV infection across MENA.12–20 The reviews
were informed by Cochrane Collaboration handbook21 and reported
their findings using the Preferred Reporting Items for Systematic
reviews and Meta-analyses (PRISMA) guidelines.22
Data sources for these reviews included peer-reviewed publications
identified through international scientific databases (PubMed and
Embase), regional and country-level scientific databases (World Health
Organization [WHO] Index Medicus for the Eastern Mediterranean
Region, the Iraqi Academic Scientific Journals’ database, Iran's Scientific
Information Database, among others), MENA HIV/AIDS Epidemiology
Synthesis Project database,23,24 abstract archives of non-indexed
international conferences, and gray literature comprised of public health
reports and routine data reporting. Broad search criteria were used
combiningmedical index termsexploded tocoverall subheadingsand free
text terms for HCV and country names, to ensure inclusiveness. No
language restrictionswere used as non-English articles were extracted by
native speakers. Screening of articles was restricted to those published
after 1989, the year in which HCV was first identified.25,26
Our definition of MENA included 24 countries: Afghanistan,
Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon,
Libya, Mauritania, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi
Arabia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates (UAE),
and Yemen. Genotype information for all articles retrieved during these
systematic literatures searches were extracted and subsequently used
to populate the HCV genotype sub-database. Individuals with untype-
ableHCV genotypes were removed from the overall sample size in each
study. Individuals with mixed HCV genotypes and subtype contributed
separately to the quantification of each genotype and subtype.
2.2 | Meta-analyses of genotype proportions
DerSimonian-Laird random-effectsmeta-analyseswith inversevariance
weighting27 were performed to estimate the country-specific pooled
mean proportion for each HCV genotype and the corresponding 95%
confidence interval (CI). The variance was stabilized using the Freeman-
Tukey type arcsine square-root transformation.28 Cochran'sQ test was
conducted to assess heterogeneity in effect size; a P-value <0.1 was
considered significant.27,29 The I2 was calculated to assess the
proportion of between-study variation in effect size that is due to
true differences between studies rather than chance.27 The meta-
analyses were performed when at least three measures were available
for each pooled category. The mean of reported proportions was
calculatedwhenever only twomeasureswere available.A genotypewas
considered dominant if the mean proportion was ≥50%, common if the
mean proportion was between 10% and 50%, and limited if the mean
proportion was <10%. Statistical analyses were performed on R version
3.1.2,30 and geographical mapping was conducted on Tableau 10.1.31
2.3 | Analyses of genotype diversity
The diversity ofHCV genotypeswas assessed by calculating the Shannon
Diversity Index, with higher scores indicating more diversity.32 Assuming
equal distribution of the seven HCV genotypes (that is highest diversity
possible),7 the highest ShannonDiversity Index score attainable is 1.95.32
2.4 | Estimation of number of HCV chronically
infected individuals with each genotype
The country-specific number of chronically infected individuals with
each genotype was calculated by multiplying the country-specific
pooled mean proportion for each genotype by the number of
individuals with chronic HCV infection in each country as estimated
by Chemaitelly et al33 The latter was calculated based onmathematical
modeling and meta-analyses using the HCV antibody prevalence and
HCV RNA prevalence sub-databases of the MENA HCV Epidemiology
Synthesis Project database.12–20 The country-specific pooled mean
proportion for each genotype was adjusted so that the sum of all
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genotype proportions totaled 100%. Demographics for each country
was obtained from the United Nations 2015 World Population
Prospects database.34
3 | RESULTS
3.1 | Scope of the evidence
Supplementary Table S1 lists the details of the 338 identified HCV
genotype studies in MENA including 82 257 genotyped individuals.
Genotype informationwas available for 20 of the 24 included countries,
15 of which had sufficient number of studies to conduct meta-analyses
(Table 1). There were too few studies from Bahrain, Kuwait, Oman,
Qatar, and Sudan to perform meta-analyses. Additionally, the study
from Sudan had an insignificant sample size (n = 4; all of which were
genotype 4), and therefore was excluded from further analyses. No
studies were identified from Djibouti, Mauritania, Somalia, and Yemen;
these countries were also excluded from further analysis. Pakistan had
the largest number of studies (n = 92) and the largest sample size of
genotyped individuals (N = 36 111). Iran was second with 66 studies
including23 134genotyped individuals. Eachof the remaining countries
had less than 10 000 genotyped individuals (Table 1).
The genotyped populations varied across these studies but often
included clinical populations at high-risk of exposure to HCV such as
thalassemia, hemophilia, and hemodialysis patients (Supplementary
Table S1). Other genotyped populations included chronic liver disease
patients, people who inject drugs (PWID), blood donors, pregnant
women, and healthcare workers, among others.
3.2 | Meta-analyses of the distribution of HCV
genotypes
Table 1 lists the estimated pooled mean proportion for each HCV
genotype by country. Figure 1 displays the distribution of genotypes
by country. Figure 2 maps the dominant genotype by country.
3.2.1 | Genotype 1
Genotype 1 was dominant (≥50%) in Algeria, Iran, Lebanon, Morocco,
Oman, Tunisia, and UAE, with the highest level observed in Tunisia at
85.9% (95%CI: 78.0-92.5). Genotype 1 was common (10-50%) in
Afghanistan, Bahrain, Iraq, Jordan, Kuwait, Lebanon, Libya, Palestine,
Qatar, Saudi Arabia, and Syria. Genotype 1 was limited (≤10%) in
Pakistan and Egypt. For the whole MENA sample, the pooled mean
proportion for genotype 1 was 30.2% (95%CI: 26.7-33.7).
3.2.2 | Genotype 2
Genotype 2was not dominant in anyMENA country, but was common
in Algeria, Bahrain, Morocco, and Libya, with the highest level
observed in Libya at 17.7% (95%CI: 15.3-20.0). Genotype 2 was
limited in remaining countries, with little to no cases observed in each
of Afghanistan, Iraq, Jordan, Kuwait, Palestine, and Syria. For thewhole
MENA sample, the pooled mean proportion for Genotype 2 was 2.5%
(95%CI: 1.6-3.4).
3.2.3 | Genotype 3
Genotype 3 was dominant in Afghanistan and Pakistan, with the
highest level observed in Pakistan at 81.4% (95%CI: 77.9-84.8).
Genotype 3 was common in Bahrain, Iran, Kuwait, Libya, Qatar, and
UAE. Genotype 3 was limited in Algeria, Iraq, Lebanon, Morocco,
Oman, Saudi Arabia, Syria, and Tunisia. Little to no cases were
observed in each of Egypt, Jordan, and Palestine. For the wholeMENA
sample, the pooled mean proportion for Genotype 3 was 26.7% (95%
CI: 22.3-31.4).
3.2.4 | Genotype 4
Genotype 4 was dominant in Egypt, Iraq, Jordan, Kuwait, Libya, Qatar,
Saudi Arabia, and Syria, with the highest level observed in Egypt at
93.1% (95%CI: 89.8-95.9). Genotype 4 was common in Bahrain,
Kuwait, Lebanon, Libya, Oman, and UAE. Genotype 4 was limited in
Algeria, Iran, Morocco, Pakistan, and Tunisia. No cases were observed
in Afghanistan. For the whole MENA sample, the pooled mean
proportion for Genotype 4 was 17.5% (95%CI: 14.2-21.0).
3.2.5 | Genotypes 5, 6, and 7
Genotype 5 was neither dominant nor common in anyMENA country.
It was limited in Syria at 7.6% (95%CI: 0.0-23.0), but otherwise was not
observed, or was observed at extremely low levels, in the remaining
MENA countries. For the whole MENA sample, the pooled mean
proportion for Genotype 5 was 0.0% (95%CI: 0.0-0.0).
Genotype 6 was not observed or was observed at extremely low
levels in all countries, leading to a pooled mean proportion of 0.0%
(95%CI: 0.0-0.0) for the whole MENA sample. Genotype 7 was not
observed in any country.
3.3 | Genotype diversity
Supplementary Table S2 lists the estimated genotype diversity by
country as assessed using Shannon Diversity Index (H). Figure 3 maps
genotype diversity across MENA. Lebanon had the highest genotype
diversity (H = 1.27 out of 1.95; 68.2%), followed by Bahrain (H = 1.24
out of 1.95; 63.7%) and UAE (H = 1.14 out of 1.95; 58.8%). Egypt had
the lowest diversity (H = 0.27 out of 1.95; 14.4%), right behind Pakistan
(0.61 out of 1.95; 33.1%) and Afghanistan (0.66 out of 1.95; 34.1%).
3.4 | Number of HCV chronically infected individuals
by genotype
Table 2 lists the estimated number of HCV chronically infected
individuals by genotype acrossMENA countries. Overall for the region,
the largest number of chronically infected individuals was that for
genotype 3 at 6.0 million, followed by genotype 4 at 5.9 million,
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TABLE 1 Country-specific pooled mean proportion for each hepatitis C virus (HCV) genotype across the Middle East and North Africa (MENA)
Studies Samples Proportion (actual studies)
Proportion (meta-
analysis) Heterogeneity measures
Country Total N Total n Range (%) Mean (%) 95%CIa Q (P-value)b I2 (confidence limits)c
Genotype 1
Afghanistan 3 71 0.0-47.8 34.6 20.8-49.5 1.7 (P = 0.440)
Algeria 7 3806 55.6-88.8 78.0 70.2-85.0 110.7 (P < 0.001) 94.6 (91.1-96.7)
Bahrain 2 107 47.9-55.6 48.6 39.3-58.0
Egypt 47 5031 0.0-25.0 2.5 1.3-4.1 177.6 (P < 0.001) 74.1 (65.5-80.5)
Iran 66 23 134 13.5-100 56.3 52.9-59.6 1022.4 (P < 0.001) 93.6 (92.5-94.6)
Iraq 19 681 0.0-71.4 34.7 22.6-47.7 143.1 (P < 0.001) 87.4 (81.8-91.3)
Jordan 4 71 0.0-73.3 22.8 0.0-66.8 31.8 (P < 0.001) 90.6 (78.9-95.8)
Kuwait 1 108 27.8 20.2-36.9
Lebanon 20 543 0.0-100 38.9 30.4-47.7 51.7 (P < 0.001) 63.3 (40.6-77.3)
Libya 6 4236 28.6-35.8 32.8 31.0-34.7 8.5 (P = 0.132) 41.0 (0.0-76.6)
Morocco 13 2636 35.6-100 69.4 53.7-83.2 386.4 (p < 0.001) 96.9 (95.8-97.7)
Oman 1 33 54.5 38.0-70.2
Pakistan 92 36 111 0.0-64.1 9.1 7.4-11.0 1962.9 (P < 0.001) 95.4 (94.8-95.9)
Palestine 4 152 8.7-50.0 19.9 7.4-35.6 5.7 (P = 0.129) 47.0 (0.0-82.4)
Qatar 1 400 19.8 16.1-23.9
Saudi Arabia 23 2652 0.0-75.0 34.4 27.5-41.6 213.2 (P < 0.001) 89.7 (85.8-92.5)
Syria 3 674 10.0-60.7 33.5 12.1-58.9 13.4 (P < 0.001) 85.0 (55.8-94.9)
Tunisia 22 1578 50.0-100 85.9 78.0-92.5 196.2 (P < 0.001) 89.3 (85.2-92.3)
UAE 4 233 26.9-75.0 52.4 30.8-73.7 23.5 (P < 0.001) 87.2 (69.4-94.7)
MENA 338 82 257 0.0-100 30.2 26.8-33.8 31841 (P < 0.001) 98.9 (98.9-99.0)
Genotype 2
Afghanistan 3 71 0.0-0.0 0.0 0.6 (P = 0.732)
Algeria 7 3806 8.6-37.0 15.3 9.6-22.0 98.8 (P < 0.001) 93.9 (89.9-96.4)
Bahrain 2 107 9.2-33.3 11.2 6.5-18.6
Egypt 47 5031 0.0-55.6 0.2 0.0-1.1 230.2 (P < 0.001) 80.0 (74.0-84.7)
Iran 66 23 134 0.0-38.0 0.4 0.0-1.0 575.1 (P < 0.001) 88.7 (86.3-90.6)
Iraq 19 681 0.0-6.0 0.0 0.0-0.0 12.2 (P = 0.838) 0.0 (0.0-24.5)
Jordan 4 71 0.0-0.0 0.0 0.0-1.1 0.4 (P = 0.933)
Kuwait 1 108 0.0 0.0-3.4
Lebanon 20 543 0.0-80.0 7.4 1.1-16.8 127.6 (P < 0.001) 85.1 (78.3-89.8)
Libya 6 4236 13.9-21.2 17.7 15.3-20.0 21.7 (P < 0.001) 76.9 (48.5-89.7)
Morocco 13 2636 0.0-63.2 16.7 4.3-34.4 614.8 (P < 0.001) 98.0 (97.5-98.5)
Oman 1 33 9.1 3.1-23.6
Pakistan 92 36 111 0.0-50.8 4.1 2.6-5.8 3041.6 (P < 0.001) 97.0 (96.7-97.3)
Palestine 4 152 0.0-4.4 0.0 0.0-1.8 3.9 (P = 0.271) 23.3 (0.0-88.3)
Qatar 1 400 0.5 0.1-1.8
Saudi Arabia 23 2652 0.0-7.4 1.4 0.4-2.8 49.3 (P < 0.001) 55.3 (28.6-72.1)
Syria 3 674 0.0-0.8 0.0 0.0-0.2 0.1 (P = 0.928)
Tunisia 22 1578 0.0-37.5 5.1 1.5-9.9 128.7 (P < 0.001) 83.7 (76.4-88.7)
UAE 4 233 0.0-33.3 1.2 0.0-6.5 7.1 (P = 0.067) 58.0 (0.0-86.0)
MENA 338 82 257 0.0-63.2 2.5 1.6-3.5 11940.7 (P < 0.001) 97.2 (97.0-97.3)
Genotype 3
Afghanistan 3 71 52.2-100 65.4 50.5-79.2 1.7 (P = 0.437) 0.0 (0.0-87.5)
Algeria 7 3806 0.0-10.4 3.0 1.6-4.9 25 (P < 0.001) 76.0 (49.3-88.6)
(Continues)
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TABLE 1 (Continued)
Studies Samples Proportion (actual studies)
Proportion (meta-
analysis) Heterogeneity measures
Country Total N Total n Range (%) Mean (%) 95%CIa Q (P-value)b I2 (confidence limits)c
Bahrain 2 107 0.0-20.4 18.7 12.4-27.1
Egypt 47 5031 0.0-33.3 0.0 0.0-0.5 164.4 (P < 0.001) 72.0 (62.6-79.1)
Iran 66 23 134 0.0-65.7 38.8 35.7-41.9 878.9 (P < 0.001) 92.6 (91.3-93.7)
Iraq 19 681 0.0-21.7 0.2 0.0-3.3 68.8 (P < 0.001) 73.8 (58.9-83.3)
Jordan 4 71 0.0-0.0 0.0 0.0-1.1 0.4 (P = 0.933) 0.0 (0.0-0.0)
Kuwait 1 108 25.0 17.8-33.9
Lebanon 20 543 0.0-58.6 7.8 2.3-15.3 78.6 (P < 0.001) 75.8 (62.8-84.3)
Libya 6 4236 6.0-21.0 13.7 9.1-19.1 112.7 (P < 0.001) 95.6 (92.6-97.3)
Morocco 13 2636 0.0-50.0 3.2 0.4-7.9 124.6 (P < 0.001) 90.4 (85.4-93.7)
Oman 1 33 9.1 3.1-23.6
Pakistan 92 36 111 0.0-100 81.4 77.9-84.8 4410.5 (P < 0.001) 97.9 (97.7-98.1)
Palestine 4 152 0.0-8.7 0.0 0.0-7.7 6.7 (P = 0.081) 55.5 (0.0-85.3)
Qatar 1 400 15.8 12.5-19.6
Saudi Arabia 23 2652 0.0-33.3 0.8 0.0-2.3 75.2 (P < 0.001) 70.7 (55.4-80.8)
Syria 3 674 0.0-1.7 0.3 0.0-1.2 0.2 (P = 0.903) 0.0 (0.0-0.0)
Tunisia 22 1578 0.0-25.0 0.7 0.0-3.4 100.3 (P < 0.001) 79.1 (68.9-85.9)
UAE 4 233 0.0-33.6 11.8 0.1-33.1 32 (P < 0.001) 90.6 (79.0-95.8)
MENA 338 82 257 0.0-100 26.8 22.4-31.5 60629.7 (P < 0.001) 99.4 (99.4-99.5)
Genotype 4
Afghanistan 3 71 0.0-0.0 0.0 0.0-0.0 0.6 (P = 0.732) 0.0 (0.0-66.6)
Algeria 7 3806 0.0-7.4 1.4 0.6-2.4 14.1 (P = 0.028) 57.5 (1.5-81.6)
Bahrain 2 107 11.1-22.4 21.5 14.8-30.2
Egypt 47 5031 22.2-100 93.1 89.8-95.9 432.6 (P < 0.001) 89.4 (86.7-91.5)
Iran 66 23 134 0.0-25.0 0.0 0.0-0.1 238.1 (P < 0.001) 72.7 (65.2-78.6)
Iraq 19 681 21.4-100 60.0 46.3-73.1 157.9 (P < 0.001) 88.6 (83.7-92.0)
Jordan 4 71 26.7-100 77.2 33.2-100 31.8 (P < 0.001) 90.6 (78.9-95.8)
Kuwait 1 108 47.2 38.1-56.6
Lebanon 20 543 0.0-100 31.5 20.6-43.4 102.6 (P > 0.001) 81.5 (72.4-87.6)
Libya 6 4236 27.6-45.3 35.3 30.2-40.6 63.96 (P < 0.001) 92.2 (85.7-95.7)
Morocco 13 2636 0.0-18.8 0.9 0.0-2.8 44.4 (P < 0.001) 72.9 (52.9-84.5)
Oman 1 33 27.3 15.1-44.2
Pakistan 92 36 111 0.0-17.1 0.1 0.0-0.6 1188.6 (P < 0.001) 92.3 (91.2-93.4)
Palestine 4 152 50.0-85.7 75.0 66.9-82.3 1.6 (P = 0.652) 0.0 (0.0-71.8)
Qatar 1 400 64.0 59.2-68.6
Saudi Arabia 23 2653 9.4-90.9 56.6 49.0-64.0 225.9 (P < 0.001) 90.3 (86.7-92.9)
Syria 3 674 39.3-60.0 53.8 40.3-67.1 4.1 (P = 0.127) 51.5 (0.0-86.0)
Tunisia 22 1578 0.0-19.4 1.7 0.0-5.3 128 (P < 0.001) 83.6 (76.3-88.7)
UAE 4 233 0.0-46.3 21.3 5.4-42.8 25.6 (P < 0.001) 88.3 (72.5-95.0)
MENA 338 82 257 0.0-100 17.3 14.1-20.6 43318.8 (P < 0.001) 99.2 (99.2-99.3)
Genotype 5
Afghanistan 3 71 0.0-0.0 0.0 0.0-0.0 0.6 (P = 0.732) 0.0(0.0-66.6)
Algeria 7 3806 0.0-0.9 0.0 0.0-0.0 6.3 (P = 0.389) 5.0 (0.0-72.3)
Bahrain 2 107 0.0-0.0 0.0 0.0-3.5
Egypt 47 5031 0.0-31.6 0.0 0.0-0.0 45.2 (P = 0.507) 0.0 (0.0-32.6)
Iran 66 23 134 0.0-3.5 0.0 0.0-0.0 89.7 (P = 0.023) 27.5 (1.2-46.8)
(Continues)
| 135
TABLE 1 (Continued)
Studies Samples Proportion (actual studies)
Proportion (meta-
analysis) Heterogeneity measures
Country Total N Total n Range (%) Mean (%) 95%CIa Q (P-value)b I2 (confidence limits)c
Iraq 19 681 0.0-0.0 0.0 0.0-0.0 3.9 (P = 0.100) 0.0 (0.0-0.0)
Jordan 4 71 0.0-0.0 0.0 0.0-1.1 0.4 (P = 0.933) 0.0 (0.0-0.0)
Kuwait 1 108 0.0 0.0-3.4
Lebanon 20 543 0.0-3.0 0.0 0.0-0.3 4.8 (P = 0.100) 0.0 (0.0-0.0)
Libya 6 4236 0.0-0.1 0.0 0.0-0.1 1.0 (P = 0.959) 0.0 (0.0-0.0)
Morocco 13 2636 0.0-0.1 0.0 0.0-0.0 3.7 (P = 0.988) 0.0 (0.0-0.0)
Oman 1 33 0.0 0.0-10.4
Pakistan 92 36 111 0.0-4.1 0.0 0.0-0.0 192.6 (P < 0.001) 52.7 (40.0-62.8)
Palestine 4 152 0.0-0.0 0.0 0.0-0.0 1.2 (P < 0.751) 0.0 (0.0-62)
Qatar 1 400 0.0 0.0-1.0
Saudi Arabia 23 2652 0.0-5.1 0.0 0.0-0.0 31.1 (P < 0.094) 29.3 (0.0-57.6)
Syria 3 674 0.0-30.0 7.6 0.0-23.0 9.1 (P < 0.010) 78.1 (29.4-93.2)
Tunisia 22 1578 0.0-0.0 0.0 0.0-0.0 7.9 (P < 0.996) 0.0 (0.0-0.0)
UAE 4 233 0.0-0.0 0.0 0.0-0.0 0.7 (P < 0.875) 0.0 (0.0-33.7)
MENA 338 82 257 0.0-31.6 0.0 0.0-0.0 706.8 (P < 0.001) 52.3 (45.9-57.8)
Genotype 6
Afghanistan 3 71 0.0-0.0 0.0 0.0-0.0 0.6 (P = 0.732) 0.0 (0.0-66.6)
Algeria 7 3806 0.0-0.0 0.0 0.0-0.0 2.4 (P = 0.882) 0.0 (0.0-26.2)
Bahrain 2 107 0.0-0.0 0.0 0.0-3.5
Egypt 47 5031 0.0-0.0 0.0 0.0-0.0 20.3 (P = 0.100) 0.0 (0.0-0.0)
Iran 66 23 134 0.0-0.7 0.0 0.0-0.0 38.8 (P = 0.100) 0.0 (0.0-0.0)
Iraq 19 681 0.0-0.0 0.0 0.0-0.0 3.9 (P = 0.100) 0.0 (0.0-0.0)
Jordan 4 71 0.0-0.0 0.0 0.0-1.1 0.4 (P = 0.933) 0.0 (0.0-0.0)
Kuwait 1 108 0.0 0.0-3.4
Lebanon 20 543 0.0-0.0 0.0 0.0-0.0 5.0 (P = 0.999) 0.0 (0.0-0.0)
Libya 6 4236 0.0-0.1 0.0 0.0-0.1 0.3 (P = 0.100) 0.0 (0.0-0.0)
Morocco 13 2636 0.0-0.0 0.0 0.0-0.0 6.5 (P = 0.888) 0.0 (0.0-20.1)
Oman 1 33 0.0 0.0-10.4
Pakistan 92 36 111 0.0-3.4 0.0 0.0-0.0 161 (P < 0.001) 43.5 (27.5-55.9)
Palestine 4 152 0.0-0.0 0.0 0.0-0.0 1.2 (P < 0.751) 0.0 (0.0-62.0)
Qatar 1 400 0.0 0.0-1.0
Saudi Arabia 23 2652 0.0-0.9 0.0 0.0-0.0 8.2 (P < 0.997) 0.0 (0.0-0.0)
Syria 3 674 0.0-0.0 0.0 0.0-0.0 1.3 (P < 0.524) 0.0 (0.0-83.9)
Tunisia 22 1578 0.0-0.0 0.0 0.0-0.0 7.9 (P < 0.996) 0.0 (0.0-0.0)
UAE 4 233 0.0-0.0 0.0 0.0-0.0 0.7 (P < 0.875) 0.0 (0.0-33.7)
MENA 338 82 257 0.0-3.4 0.0 0.0-0.0 317.3 (P < 0.001) 0.0 (0.0-7.4)
Djibouti, Mauritania, Somalia, Sudan, and Yemen excluded due to either no studies available or small sample size.
aCI: Confidence interval.
bQ: The Cochran Q statistic is a measure assessing the existence of heterogeneity in effect size (proportion of each genotype).
cI2: Ameasure assessing themagnitude of between-study variation that is due to differences in effect size (proportion of each genotype) across studies rather
than chance.
136 |
genotype 1 at 2.0 million, and genotype 2 at 0.4 million. Genotype 5
contributed a mere 10 500 infections with virtually no contribution for
genotype 6. The vast majority of genotype 3 chronically infected
individuals were in Pakistan (5.7 out of 6.0 million), and the vast
majority of genotype 4 infected individuals were in Egypt (5.0 out of
5.9 million).
Weighted by population size in each country, the highest
proportion of chronically infected individuals was that of genotype
3 (41.9%), followed by genotype 4 (41.0%), genotype 1 (14.2%),
genotype 2 (2.9%), genotype 5 (0.1%), and genotype 6 (0.0%).
4 | DISCUSSION
We presented a comprehensive characterization of HCV genotype
distribution, diversity, and patterns in MENA. We found that the
distribution varied from one country to another, with evidence for sub-
regionalization patterns for specific genotypes. Most chronically
infected individuals were infected with genotypes 3 or 4, with nearly
equal contributions for each at just over 40%. However, these large
contributions merely reflected the dominance of these genotypes in
Pakistan (genotype 3) and Egypt (genotype 4), by far the largest two
HCV epidemics in MENA. Over 75% of MENA's chronically infected
individuals are found in these two countries.33
While genotype 1 was present throughout the region, and was
dominant or common inmost countries, it had limited presence in both
Egypt and Pakistan, and hence its contribution did not exceed 15%.
Genotypes 2, 5, 6, and 7 did not have significant presence in MENA.
While there was considerable genotype diversity in most countries,
there was limited diversity in both Egypt and Pakistan. These findings
inform the current expansion of DAA treatment programs in MENA,
and provide insights about the transmission pathways of this infection.
FIGURE 1 The country-specific distribution of hepatitis C virus (HCV) genotypes across the Middle East and North Africa (MENA) region.
Legend: ‡ Countries in which less than three studies were available. Djibouti, Mauritania, Somalia, Sudan, and Yemen were excluded either
due to no studies available or small sample size
FIGURE 2 Map of the dominant hepatitis C virus (HCV) genotype across countries of the Middle East and North Africa (MENA) region.
Legend: Djibouti, Mauritania, Somalia, Sudan, and Yemen were excluded either due to no studies available or small sample size
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The distribution of HCV genotypes in MENA appears to reflect
three sub-regional patterns (Figure 2). The first is that of dominance of
genotype 3, a pattern found in Pakistan and Afghanistan, and to some
extent in Iran (Figures 1 and 2). This pattern is possibly explained by the
fact that these are neighboring countries with mass cross-border
population movements and porous borders.35,36
The second pattern is that of dominance, or large presence, of
genotype 4which is found in Egypt, its neighboring countries, and/or in
countries that host or have hosted large migrant labor populations
from Egypt15,18,37 (Figures 1 and 2). This pattern is possibly explained
by the unique nature of the Egyptian epidemic,12,38 which has led to
circulation of genotype 4 through population movement to countries
with strong links to Egypt. Countries that have imported large Egyptian
labor populations included Iraq, Jordan, Kuwait, Libya, Oman, Qatar,
Saudi Arabia, and UAE.39 It bears notice, nonetheless, that the
circulation of this genotype out of Egypt does not seem to have
impacted significantly HCV prevalence in these countries. HCV
prevalence in these countries is much lower than that in
Egypt.12,13,15,18,38
The third pattern is that of dominance, or large presence, of
genotype 1 which is found in the Maghreb sub-region of MENA
(Algeria, Morocco, Tunisia, and to some extent Libya), part of the
Arabian Gulf sub-region (Oman and UAE), Iran, and to some extent
Lebanon (Figure 2). This pattern is similar to the most common global
pattern,7,9 and may reflect population movement links with countries
outside MENA, such as the Maghreb sub-region migration links with
Western and Southern Europe.40,41 There are also large and diverse
expatriate populations in the Arabian Gulf sub-region, and this may
have contributed to this pattern.18
While these three patterns are largely distinct, some overlap is
seen such as for countries that border different patterns—Iran and
Libya provide two examples (Figures 1 and 2). The Arabian Gulf sub-
region also exhibits such overlap with its diverse migrant-population
composition—as reflected in the high genotype diversity for the
majority of Arabian Gulf countries (Figure 3, Supplementary Table S2).
Lastly, genotype 2 was mainly present in the Maghreb sub-region,
possibly because of geographic proximity and population links with
West Africa where this genotype is most frequent.7,42,43
Genotype diversity varied across the region. The variability in
genotype diversity is probably attributable to factors including, among
others, specific historical events, such as the case for Egypt,12,38,44
how HCV was introduced to each country, such as through migrant
population movements,40,41 and importation of blood products
(mostly from Western countries) before the onset of HCV blood
screening,24,45 Genotype diversity appears also to be influenced by the
type of drivers of HCV transmission in each country, such as the role of
PWID and association with genotype 3.46,47
PWID may play a larger relative role in HCV transmission in the
future, as exposures in the wider population are further controlled.
Injecting drug use is a major challenge in MENA,48,49 but we found a
small number of genotype studies among PWID. Available data
suggests that the genotypes circulating among PWID in a given
country, tend to be similar to those circulating in the wider population
in this country (Supplementary Table S1). We are thus unable to see
whether there are associations between specific genotypes and
injecting drug use, such as the genotype 3 link seen in the global
literature.7,50,51 As suggested by recent studies, however, there seems
to be a shift toward genotype 3 in Iran.46,47 This is particularly among
young patients, and is apparently linked to injecting drug use
increasingly becoming the main route of HCV transmission.46,47
Our study has several limitations. We did not find HCV genotype
studies for four MENA countries, and there were too few studies to
conduct meta-analyses for another five countries. The number of
studies also varied by country, and sample size of genotyped
individuals was small for a number of studies. Studies may have also
sampled populations from specific geographic areas within a given
country, or select sub-populations. We did not assess secular trends in
genotype distribution, such as using meta-regressions, as such
analyses are challenged by the heterogeneity in available data and
by the fact that genotype diversity is very low in the two countries that
contribute most chronic infections in this region (namely, Egypt and
Pakistan; Table 2). Accordingly, available genotype data may not have
FIGURE 3 Map showing the genotype diversity across countries of the Middle East and North Africa (MENA) region, quantified by
Shannon Diversity Index. Legend: Djibouti, Mauritania, Somalia, Sudan, and Yemen were excluded either due to no studies available or small
sample size
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captured the diversity and true distribution of genotypes in the wider
population of each country.
Key strengths of our study are the systematic and comprehen-
sive searches that yielded our input data, and the fact that we
synthesized and analyzed these data using state of the art
quantitative methods. In addition to international databases, we
identified a volume of data through regional and national databases,
and included non-English articles, public health reports, and routine
data reporting. We have therefore identified much more data than is
present in existing global or regional studies of HCV genotypes,7,9,52
and presented a detailed picture of HCV genotypes and their
patterns and diversity in MENA.
In conclusion, genotypes 3 and 4 are themost common genotypes in
MENA, with equal contributions, in large part because of the sizable HCV
epidemics in Pakistan and Egypt. While genotype 1 was ubiquitous, and
was dominant or common in most countries, its overall contribution was
still small compared to those of genotypes 3 and 4. Three sub-regional
genotype patterns were identified, and these appeared to reflect cross-
border population movements and geographic proximity. Two patterns
were centered in each of Pakistan (genotype 3 pattern) and Egypt
(genotype 4 pattern), while the third (genotype 1 pattern)was similarwith
themost common global pattern.While genotype diversity was limited in
Egypt and Pakistan, it was considerable in the other countries. Genotypes
2, 5, 6, and 7 did not have significant presence. These findings inform the
DAA treatment programs that are being expanded inMENA, and provide
insights into HCV transmission pathways.
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